360° view Sample input On-board reagents Available assays

QIAstat-Dx Cartridge

MAIN port

Any liquid sample type up to 1.5 mL

INNOVATIVE solution

All reagents on-board to provide comprehensive results
in about an hour

Discover the QIAstat-Dx Analyzer

The next generation of multiplex syndromic testing

Explore features
Onboard sample prep
Dimension (WxHxD): 4 ¼ x 2 1/16 x 1 inches
Traceability barcode
Main port
Onboard reagent storage
Reaction chambers
Visual confirmation of loaded sample
Sealed cartridge design

QIAstat-Dx Cartridge

A fully-contained test that can detect 20 or more targets*. Simply add the sample and let the QIAstat-Dx system do the rest.

*depending on respiratory panel type

Available assays:

QIAstat-Dx Respiratory Panel

True Sample to Insight solution for patients with suspected upper respiratory infections

  • Detects 20 viral and bacterial targets in about an hour
  • Wet and dry reagents on-board
  • No precision pipetting required
  • Room temperature storage

Download the flyer

The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.

QIAstat-Dx Respiratory Panel

QIAstat-Dx Respiratory SARS-CoV-2 Panel (Emergency Use Authorization)

This expanded version of our multiplex respiratory cartridge detects and differentiates 21 viral and bacterial respiratory targets, including SARS-CoV-2.

Download the flyer

The QIAstat-Dx Analyzer and the QIAstat-Dx Respiratory Panel are intended for in vitro diagnostic use.

QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use under Emergency Use Authorization Only. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel has not been FDA cleared or approved;

The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized by FDA under an EUA for use by authorized laboratories;

The QIAstat-Dx Respiratory SARS-CoV-2 Panel has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms;

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

QIAstat-Dx Respiratory SARS-CoV-2 Panel

See QIAstat-Dx in action

X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm